Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer

Published:2020-04 Issue:2 Volume:18 Page:e180-e189
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Smith Matthew R.,Mehra Maneesha,Nair Sandhya,Lawson Joe,Small Eric J.

Funder

Janssen Research & Development

LLC

Bayer

Clovis

Gilead

Janssen

Lilly

Janssen Global Services

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference20 articles.

1. Characterising the castration-resistant prostate cancer population: a systematic review;Kirby;Int J Clin Pract,2011

2. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer;Hussain;N Engl J Med,2018

3. The development of intermediate clinical endpoints in cancer of the prostate (ICECaP);Sweeney;J Natl Cancer Inst,2015

4. Apalutamide treatment and metastasis-free survival in prostate cancer;Smith;N Engl J Med,2018

5. Darolutamide in nonmetastatic, castration-resistant prostate cancer;Fizazi;N Engl J Med,2019

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world;Frontiers in Oncology;2024-04-18

2. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice;Irish Journal of Medical Science (1971 -);2023-03-22

3. Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer;Investigational New Drugs;2022-08-17

4. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer;ESMO Open;2022-06

5. Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer;Cancer Science;2022-05-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3